| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 34.25B | 36.80B | 35.46B | 33.48B | 27.77B |
| Gross Profit | 8.12B | 9.54B | 9.35B | 10.50B | 7.88B |
| EBITDA | 4.84B | 6.37B | 6.41B | 7.71B | 5.43B |
| Net Income | 3.59B | 4.76B | 4.75B | 5.86B | 4.18B |
Balance Sheet | |||||
| Total Assets | 35.47B | 36.10B | 32.58B | 30.35B | 24.02B |
| Cash, Cash Equivalents and Short-Term Investments | 2.99B | 4.52B | 3.87B | 2.54B | 3.21B |
| Total Debt | 6.03B | 5.97B | 5.14B | 6.11B | 5.45B |
| Total Liabilities | 10.73B | 10.28B | 9.44B | 10.57B | 8.80B |
| Stockholders Equity | 24.19B | 25.31B | 22.70B | 19.40B | 14.89B |
Cash Flow | |||||
| Free Cash Flow | 3.28B | 2.02B | 4.16B | 413.60M | 267.00M |
| Operating Cash Flow | 3.42B | 2.19B | 4.30B | 561.80M | 534.40M |
| Investing Cash Flow | -168.70M | -190.60M | -310.20M | -414.90M | -252.20M |
| Financing Cash Flow | -4.76B | -1.36B | -2.67B | -811.20M | -85.10M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $13.73B | 10.71 | 16.89% | 0.70% | 1.11% | -10.03% | |
74 Outperform | $24.38B | 11.25 | 17.67% | 0.78% | 1.76% | -4.24% | |
73 Outperform | $43.12B | 13.51 | 13.63% | 1.14% | -6.93% | -19.41% | |
71 Outperform | $5.96B | 7.42 | 14.31% | ― | 6.98% | 9.74% | |
70 Outperform | $21.68B | 17.65 | 33.18% | ― | 3.61% | -6.94% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
60 Neutral | $26.76B | 13.69 | 8.26% | 1.91% | -3.78% | -44.21% |
On January 15, 2026, D.R. Horton, Inc. held its Annual Meeting of Stockholders, where shareholders elected eight director nominees to serve until the 2027 annual meeting, indicating continued support for the company’s existing board composition and governance framework. Investors also approved the company’s executive compensation on an advisory basis and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending September 30, 2026, reinforcing continuity in leadership oversight and financial auditing practices that underpin the company’s operational and reporting stability.
The most recent analyst rating on (DHI) stock is a Hold with a $162.00 price target. To see the full list of analyst forecasts on DR Horton stock, see the DHI Stock Forecast page.